NeurologyLive® Friday 5 — January 17, 2024

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Overviewing Updating Amyloid and Tau PET Criteria to Enhance Alzheimer Diagnostic Precision: Phillip Kuo, MD, PhD, FACR

The professor in the department of diagnostic radiology at City of Hope discussed a newly updated published guideline for amyloid and tau PET imaging geared towards improving Alzheimer diagnosis. [WATCH TIME: 5 minutes]

2: Advancing Understanding of the Preclinical Phase of Multiple Sclerosis: Christina J. Azevedo, MD

At the 2024 ECTRIMS Congress, the associate professor of clinical neurology at Keck School of Medicine of USC talked about recent research that highlights the preclinical phase of multiple sclerosis. [WATCH TIME: 9 minutes]

3: Impact of COVID-19 Vaccination on Neurologic Manifestations of Long COVID: Igor Koralnik, MD

The chief of neuroinfectious diseases and global neurology at Northwestern Medicine discussed a recently published study that highlighted Long COVID’s significant clinical and societal impact. [WATCH TIME: 5 minutes]

4:NeuroVoices: Nigel Bunnett, PhD, BSc, on Identifying a Novel Therapeutic Target for Chronic Pain

The professor and chair of the Department of Molecular Pathobiology at NYU College of Dentistry discussed groundbreaking research on chronic pain, focusing on the discovery of new mechanisms involving nerve growth factor and its receptors.

5: Clinical Program and Next Steps for Zorevunersen as Potential Disease-Modifying Treatment for Dravet: Barry Ticho, MD, PhD

The chief medical officer at Stoke Therapeutics discussed recent developments for zorevunersen, including the significance of breakthrough therapy designation and its plan for a phase 3 trial. [WATCH TIME: 5 minutes]